Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis

Efe, Cumali; Al Taii, Haider; Ytting, Henriette; Aehling, Niklas; Bhanji, Rahima; Hagstrom, Hannes; PÜRNAK, TUĞRUL; Muratori, Luigi; Werner, Marten; Muratori, Paolo; Klintman, Daniel; Schiano, Thomas; Montano-Loza, Aldo; Berg, Thomas; Larsen, Fin; Alkhouri, Naim; Ozaslan, Ersan; Heneghan, Michael; Yoshida, Eric; Wahlin, Staffan

doi:10.1007/s10620-018-5011-x

Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis

Atıf İçin Kopyala

Efe C., Al Taii H., Ytting H., Aehling N., Bhanji R. A., Hagstrom H., ...Daha Fazla

DIGESTIVE DISEASES AND SCIENCES, cilt.63, sa.5, ss.1348-1354, 2018 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 63 Sayı: 5
Basım Tarihi: 2018
Doi Numarası: 10.1007/s10620-018-5011-x
Dergi Adı: DIGESTIVE DISEASES AND SCIENCES
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1348-1354
Hacettepe Üniversitesi Adresli: Evet

Özet

We studied the efficacy and safety of mycophenolate mofetil (MMF) and tacrolimus as second-line therapy in pediatric patients with autoimmune hepatitis (AIH) who were intolerant or non-responders to standard therapy (corticosteroid and azathioprine).